Stable, high-producing cell lines form the foundation of every successful biologics program.
We develop expression systems that unite scientific quality, long-term stability, and regulatory clarity — supporting predictable performance across CHO, SP2/0, and NS0 hosts and biomolecules including antibodies (IgG1, IgG2, IgG4, and bispecific formats), Fc-fusion proteins, glycohormones, enzymes, cytokines, and clotting factor.
Our workflows follow a CQA-driven strategy — from vector design and clone screening to early analytics — ensuring product quality and consistency, productivity, genetic and metabolic stability, and well-grounded CMC decisions.
We combine sound scientific principles with established technologies to ensure every clone is genetically and metabolically stable, well-characterized, and ready for process development.
Our deliverables create clarity and stability — providing a strong basis for subsequent process development and scale-up.
Our cell line development work is built on consistent, reproducible execution across a wide range of molecule formats and expression systems. The scope and outcomes of this work are documented in our Track Record.
You are currently viewing a placeholder content from Vimeo. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from YouTube. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou need to load content from reCAPTCHA to submit the form. Please note that doing so will share data with third-party providers.
More Information
